Treating opioid addiction in hospitalized medical patients Miriam Komaromy, MD, FACP Associate Director, ECHO Institute.

Slides:



Advertisements
Similar presentations
Dosing and patient management requirements during induction, stabilization, and detoxification with buprenorphine Matthew A. Torrington MD Clinical Research.
Advertisements

Medication Assisted Treatment: An Introduction Deborah A. Orr, Ph.D., RN Remington College School of Nursing.
Swinomish Wellness Program
Clinical Use of Buprenorphine Finding The Right Dose Paul P. Casadonte MD California Society of Addiction Medicine 2002.
Sublingual Buprenorphine and Pain
Injectable Opioid Treatment in England Clinical Experience Rob van der Waal.
Copyright Alcohol Medical Scholars Program 1 Opioid Agonist Treatment: “Trading one substance for another?” Joseph Sakai, M.D.
Methadone in Opioid Addiction David Kan, M.D. University of California San Francisco VA Medical Center San Francisco.
 A patient admitted to your ward is on methadone maintenance 120mg daily and had his normal dose earlier today  He was admitted after he stopped taking.
What are “opiates”? heroin Morphine MS Contin oxycodone Oxycontin & Percocet hydrocodone Vicodin Codeine Tylenol # 3 hydromorphone Dilaudid meperidine.
Stapleford-Athens 2011 International Addiction Conference Developing a rehab program with NTX as one entry requirement Dr George O’Neil
Diagnosis And Treatment Of Prescription Opioid Dependence Steven W. Clay, D.O. Associate Professor, Department of Family Medicine Ohio University College.
Nelson Alcohol and Other Drug Service Nelson Alcohol and Other Drug Service GP CME Presentation March 2009.
1 Mental Health and Substance Abuse Services Division Association of Substance Abuse Providers Mike Maples October 5, 2011.
The Value of Ongoing Evaluation in Adopting Buprenorphine-Naloxone Short-term Taper Gregory S. Brigham, Ph.D. Maryhaven, Columbus, Ohio NIDA CTN Ohio Valley.
BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS Module III – Buprenorphine 101.
Medication Assisted Therapy for Opioid Addiction: Methadone and Buprenorphine Andrew J. Saxon, M.D. Veterans Affairs Puget Sound Health Care System and.
OPIOID SUBSTITUTION THERAPY
Opioid Use: What are the technological, clinical, ethical, and regulatory issues? Michael Von Korff Group Health Research Institute.
Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006
For Pain or Not for Pain: Methadone Madness
Buprenorphine Therapy in Primary Care: One Prescriber’s Experience Pittsburgh, PA August 24, 2005 Melinda Campopiano, M.D. Baron Edmond de Rothschild Chemical.
Module IV: Identification of Patients for Buprenorphine Treatment BUPRENORPHINE TREATMENT: A Training For Multidisciplinary Addiction Professionals.
Allegheny County Overdose Prevention Coalition
 Methadone is prescribed to relieve moderate to severe pain that has not been relieved by non-narcotic pain relievers.
Problem Behaviors Norman Wetterau. Less serious Ran of out pills three days early After one year lost pills Had a headache and a friend gave her a vicodin.
Spontaneous Awakening and Breathing Trials Brad Winters MD, PhD March 14, 2013.
Table 1. Prediction model for maximum daily dose of buprenorphine-naloxone in a 12-week treatment condition Baseline Predictors Maximum Daily Dose Standardized.
Injection Drug Use and Hepatitis C What Can We Do About It? Wilson M. Compton, M.D., M.P.E. Deputy Director National Institute on Drug Abuse.
BUPRENORPHINE TREATMENT: A Training For Addiction Professionals BUPRENORPHINE TREATMENT: A Training For Multidisciplinary Addiction Professionals Module.
Medication Assisted Treatment: “Getting it Right” Deborah Acker RN, CFN Nurse Service Administrator Division of Protection and Permanency Department for.
Don Teater MD Medical Advisor National Safety Council Itasca, IL Medical Provider Behavioral Health Group Asheville, NC Medical Provider Meridian Behavioral.
Ten Years of Pharmacotherapy Trials in the CTN: An Overview.
Prevention, Identification and Treatment of Opioid Use Disorders: A Personal Perspective Leah Bauer, MD Medical Director, Addiction Resource Center, Mid.
Buprenorphine {Suboxone®, Subutex®}
What the National Institute on Drug Abuse’s Clinical Trials Network Can Do for You? Major Findings from Medication Trials and Implications for Community-Based.
Buprenorphine Daryl Shorter, MD Michael E. DeBakey VA Medical Center Menninger Department of Psychiatry and Behavioral Science Baylor College of Medicine.
Benjamin J. Pariser, DO RASE Physician.  This presentation will review the option of Medication Assisted Treatment as part of a comprehensive recovery.
Opioid Tapering Paul Coelho, MD David Tauben, MD Melissa Weimer, DO, MCR.
Introduction to Suboxone What Family Physicians Can Offer Friday April 15th, 2016 John L Bender, MD, MBA,FAAFP.
Medication Assisted Treatment for Opioid Use Disorders
Benjamin Nordstrom MD, PhD VP, Medical Director for Program Development Phoenix House Foundation.
Opioids Tapering Melissa B. Weimer, DO, MCR. Disclosures Dr. Weimer is a consultant for INFORMed, IMPACT education, and the American Association of Addiction.
Suboxone and Opioid Trends Joseph Merrill M.D., M.P.H. University of Washington June 16, 2009.
Medications for the Treatment of Opioid Addiction Robert P. Schwartz, M.D. Friends Research Institute.
Medication Assisted Treatment Daniel T. Brown, D.O. Medical Director, Meridian HealthCare.
Gregory S. Brigham, Ph.D., CEO
Opioid Medication Assisted Tx (1)
Medication-Assisted Therapy at Coleman Profession Services
What are “opiates”? heroin
Acute Pain Management for Patients Receiving Buprenorphine Therapy
Improving the Discharge Process for Hospitalized Patients with Alcohol Use Disorders John Stephens March 22, 2016.
Opioids – A Pharmaceutical Perspective on Prescription Drugs
Primary Care and Comprehensive Pain Plan
Medication-Assisted Treatment 101: Breaking the Stigma
Pain Management: Patients Maintained on Buprenorphine
Treating Opioid Withdrawal with Buprenorphine/Naloxone
RIDOC BASED MAT FOR OPIATE USE DISORDERS
NCBH MAT Learning Community
Interdisciplinary Treatment for Opioid Use Disorder in the UAMS Women’s Mental Health Program – A Case Study Michael A. Cucciare, PhD and Shona Ray-Griffith,
Dr. Meldon Kahan Provincial Counsellor Call April 12, 2019
Medication Assisted Treatment: Changing the Trajectory of the Opioid Epidemic
Treating Opioid Withdrawal with Buprenorphine/Naloxone
Medically assisted treatment
Medication Assisted Treatment of Opioid Use Disorder
Treating Opioid Use Disorder
Treatment of Opioid Use Disorder
Harm Reduction Approach to Treatment of All Substance Use Disorders
The Silent Killer in America
Bassett-UMass MAT ECHO.
Presentation transcript:

Treating opioid addiction in hospitalized medical patients Miriam Komaromy, MD, FACP Associate Director, ECHO Institute

Mr. L is a 34 yo man who is admitted with suspected endocarditis. He is an active injection drug user, and was injecting heroin just prior to admission. He is alarmed about his medical condition, and is initially cooperative with treatment. However, a few hours after admission he begins to become restless and agitated. You prescribe clonidine for suspected opioid withdrawal. At 6 AM the floor nurse calls to tell you that the patient has left the hospital AMA.

What options are available to treat impending opioid withdrawal in an inpatient? Buprenorphine is safe Can prescribe as a taper or maintenance Much more effective than clonidine for withdrawal Will retain patients in the hospital for treatment of their medical illness Humane, and makes patient management easier Gowing L, Cochrane Database 2009

Who can prescribe buprenorphine to a hospitalized patient? Any physician; a buprenorphine “waiver” is not required when treating an inpatient SAMHSA website FAQ:

How should buprenorphine be prescribed to a hospitalized opioid-addicted patient? Write orders to begin treatment with buprenorphine once mild-to-moderate withdrawal symptoms are present Clinical Opiate Withdrawal Score (COWS) can be used to measure this Start patient with a 4 mg test dose, and if it is well tolerated then give additional 4 mg every 2 hours until withdrawal symptoms resolve or 12 mg is reached on day 1. Subsequent daily dose can increase to 16 mg/day if needed. Continue this dose daily until discharge (if maintenance can be arranged) or until 3 days prior to discharge, when dose should be tapered off. Can rx either buprenorphine monoproduct or buprenorphine/naloxone combo (Suboxone) Must be administered sublingually

Clinical Opioid Withdrawal Score (COWS) Pulse rateSweating RestlessnessPupil size Bone/join achesRunny nose/tearing GI UpsetTremor YawningAnxiety/irritability Gooseflesh skin Score = mild-to-moderate withdrawal

Caveats Do not initiate buprenorphine if the patient has been using methadone within the past week or the UDS is (+) for methadone Do not initiate buprenorphine if the patient is not opioid-dependent (in which case, the patient will not develop withdrawal symptoms) Risk of respiratory suppression from buprenorphine is almost non-existent for adults UNLESS high-dose benzos are co-administered, so: Do not use bup in a patient who needs high-dose benzos, eg active alcohol withdrawal Total daily bup dose can be given as a q day dose, except in patients with pain; divide TID-QID for better analgesia Bup interferes with effect of other opiates, but is itself a potent analgesic

What about buprenorphine maintenance? Maintenance treatment with buprenorphine is highly effective at reducing relapse, injection drug use, HIV and Hep C infection 1, and death Bup is covered by Medicaid without prior authorization Unfortunately, there are far too few bup prescribers in NM, and arranging for a patient to transfer to maintenance therapy is hard ASAP: Socorro Lopez-Mezon RN works to arrange rapid intake into ASAP for patients being discharged from UNM. # First Choice: patients who have primary care at FCCH can usually get bup maintenance there Page K, JAMA Int Med 2014

72% of inpatients randomized to maintenance buprenorphine with linkage to outpatient bup treatment successfully entered maintenance outpatient treatment, vs. 12% of inpatients randomized to 5 day bup taper. Liebschutz J, JAMA Int Med 2014

Buprenor -phine Placebo Retained at 1 yr 70%0 % died 020% Trial of buprenorphine 40 Heroin addicts Buprenorphine 16 mg/day vs taper + placebo All received counseling, groups Followed for 1 year Kakko et al, Lancet 2003

Schwartz, AJPH, 2012 Heroin overdose deaths fell by 2/3 as buprenorphine MAT availability increased in Baltimore Evidence continues to grow showing that buprenorphine saves lives…

Warning: if a patient is tapered off of opioids the patient MUST be warned that their tolerance will be lowered and they can easily overdose and die after discharge if they resume the same dose of opioids (RR of death 15) Ravndal E, Drug Alcohol Depend 2010

Ms. R is a 42 year-old woman who develops gall-stone-related pancreatitis. She is hospitalized for treatment and pain control. On admission, she reports that she is on maintenance therapy with Suboxone (buprenorphine/naloxone) 16 mg per day for treatment of Opioid Use Disorder. UDS (+) for buprenorphine, (-) for methadone and benzos. She is having marked abdominal pain. How would you manage her pain?

Management of pain in patients treated with buprenorphine Options include: Managing pain with buprenorphine: divide dose TID-QID, and increase total dose as needed for analgesia up to 32 mg or more per day Continuing buprenorphine but “overriding it”: Fentanyl has an even higher affinity for the mu opioid receptor than bup, so provides effective analgesia Stopping buprenorphine and beginning pain management with other opioids, with plan to resume bup prior to discharge Make an explicit plan with patients about resuming buprenorphine

Ms S is a 64 year old woman who has been treated for 5 years with oxycodone for pain from spinal stenosis. She is hospitalized after being found unconscious by her husband in what appears to be an accidental overdose. How would you address her ongoing pain and also her overdose risk?

Buprenorphine can be prescribed off label for patients who do not meet DSM criteria for Opioid Use Disorder (opioid addiction) Useful in patients who have major risks of overdose or other complications from standard opioids Safer, no tolerance, no sedation, and no development of opioid-induced hyperalgesia Not recommended for use in patients treatment with benzodiazepines because of overdose risk

Mr. J is a 50 year old man who is hospitalized for pneumonia and alcohol withdrawal. He has a long history of Alcohol Use Disorder, and has attempted to stop drinking many times without prolonged success. After several days of treatment he is preparing for discharge. What could you offer to help him to maintain his sobriety?